Sequent Scientific Limited (SEQUENT) - Net Assets

Latest as of September 2025: Rs8.87 Billion INR ≈ $95.87 Million USD

Based on the latest financial reports, Sequent Scientific Limited (SEQUENT) has net assets worth Rs8.87 Billion INR (≈ $95.87 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs17.26 Billion ≈ $186.67 Million USD) and total liabilities (Rs8.40 Billion ≈ $90.80 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Sequent Scientific Limited (SEQUENT) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs8.87 Billion
% of Total Assets	51.36%
Annual Growth Rate	21.25%
5-Year Change	-0.77%
10-Year Change	-18.73%
Growth Volatility	98.0

Sequent Scientific Limited - Net Assets Trend (2006–2025)

This chart illustrates how Sequent Scientific Limited's net assets have evolved over time, based on quarterly financial data. Also explore SEQUENT current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Sequent Scientific Limited (2006–2025)

The table below shows the annual net assets of Sequent Scientific Limited from 2006 to 2025. For live valuation and market cap data, see Sequent Scientific Limited stock valuation.

Year	Net Assets	Change
2025-03-31	Rs7.70 Billion ≈ $83.31 Million	+8.05%
2024-03-31	Rs7.13 Billion ≈ $77.10 Million	-4.84%
2023-03-31	Rs7.49 Billion ≈ $81.02 Million	+1.23%
2022-03-31	Rs7.40 Billion ≈ $80.04 Million	-4.66%
2021-03-31	Rs7.76 Billion ≈ $83.96 Million	+6.08%
2020-03-31	Rs7.32 Billion ≈ $79.15 Million	-2.02%
2019-03-31	Rs7.47 Billion ≈ $80.78 Million	+9.11%
2018-03-31	Rs6.85 Billion ≈ $74.03 Million	-31.13%
2017-03-31	Rs9.94 Billion ≈ $107.50 Million	+4.86%
2016-03-31	Rs9.48 Billion ≈ $102.51 Million	+297.95%
2015-03-31	Rs2.38 Billion ≈ $25.76 Million	+288.55%
2014-03-31	Rs613.06 Million ≈ $6.63 Million	-38.44%
2013-03-31	Rs995.83 Million ≈ $10.77 Million	-22.21%
2012-03-31	Rs1.28 Billion ≈ $13.84 Million	-5.14%
2011-03-31	Rs1.35 Billion ≈ $14.60 Million	+20.73%
2010-03-31	Rs1.12 Billion ≈ $12.09 Million	+175.87%
2009-03-31	Rs405.20 Million ≈ $4.38 Million	-29.37%
2008-03-31	Rs573.71 Million ≈ $6.20 Million	+64.27%
2007-03-31	Rs349.24 Million ≈ $3.78 Million	+76.31%
2006-03-31	Rs198.08 Million ≈ $2.14 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Sequent Scientific Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 6723.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs1.25 Billion	17.79%
Common Stock	Rs500.60 Million	7.11%
Other Comprehensive Income	Rs-3.89 Billion	-55.20%
Other Components	Rs9.18 Billion	130.31%
Total Equity	Rs7.04 Billion	100.00%

Sequent Scientific Limited Competitors by Market Cap

The table below lists competitors of Sequent Scientific Limited ranked by their market capitalization.

Company	Market Cap
Brainsway Ltd NASDAQ:BWAY	$529.64 Million
mF International Limited Ordinary Shares NASDAQ:MFI	$529.69 Million
V-Mart Retail Limited NSE:VMART	$529.72 Million
Kaveri Seed Company Limited NSE:KSCL	$529.76 Million
Zhejiang Dibay Electric Co Ltd SHG:603320	$529.03 Million
ADENTRA INC. F:UQ0	$528.89 Million
Suli Co Ltd SHG:603585	$528.64 Million
Shanghai Yahong Moulding Co Ltd SHG:603159	$528.55 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Sequent Scientific Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 6,565,600,000 to 7,044,700,000, a change of 479,100,000 (7.3%).
Net income of 218,800,000 contributed positively to equity growth.
Share repurchases of 74,500,000 reduced equity.
New share issuances of 74,500,000 increased equity.
Other comprehensive income decreased equity by 20,080,000.
Other factors increased equity by 280,380,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs218.80 Million	+3.11%
Share Repurchases	Rs74.50 Million	-1.06%
Share Issuances	Rs74.50 Million	+1.06%
Other Comprehensive Income	Rs-20.08 Million	-0.29%
Other Changes	Rs280.38 Million	+3.98%
Total Change	Rs-	7.30%

Book Value vs Market Value Analysis

This analysis compares Sequent Scientific Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 7.08x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 31.78x to 7.08x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-03-31	Rs6.09	Rs193.72	x
2007-03-31	Rs10.48	Rs193.72	x
2008-03-31	Rs11.71	Rs193.72	x
2009-03-31	Rs3.62	Rs193.72	x
2010-03-31	Rs10.24	Rs193.72	x
2011-03-31	Rs11.22	Rs193.72	x
2012-03-31	Rs11.17	Rs193.72	x
2013-03-31	Rs8.37	Rs193.72	x
2014-03-31	Rs4.39	Rs193.72	x
2015-03-31	Rs6.38	Rs193.72	x
2016-03-31	Rs45.06	Rs193.72	x
2017-03-31	Rs40.53	Rs193.72	x
2018-03-31	Rs26.55	Rs193.72	x
2019-03-31	Rs28.96	Rs193.72	x
2020-03-31	Rs28.01	Rs193.72	x
2021-03-31	Rs29.36	Rs193.72	x
2022-03-31	Rs27.60	Rs193.72	x
2023-03-31	Rs27.94	Rs193.72	x
2024-03-31	Rs26.36	Rs193.72	x
2025-03-31	Rs27.37	Rs193.72	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Sequent Scientific Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 3.11%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 1.41%
• Asset Turnover: 0.97x
• Equity Multiplier: 2.27x
Recent ROE (3.11%) is above the historical average (-9.43%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	18.94%	11.60%	1.18x	1.39x	Rs17.72 Million
2007	24.55%	19.17%	0.90x	1.43x	Rs50.83 Million
2008	4.40%	3.37%	0.75x	1.75x	Rs-32.15 Million
2009	-73.10%	-10.18%	0.56x	12.74x	Rs-166.64 Million
2010	34.43%	13.15%	0.74x	3.51x	Rs265.50 Million
2011	-0.14%	-0.06%	0.69x	3.66x	Rs-124.82 Million
2012	-1.14%	-0.40%	0.63x	4.47x	Rs-136.52 Million
2013	-68.10%	-19.84%	0.56x	6.17x	Rs-741.94 Million
2014	-194.78%	-28.08%	0.63x	10.98x	Rs-1.16 Billion
2015	-11.76%	-2.44%	0.49x	9.94x	Rs-198.65 Million
2016	-1.95%	-3.07%	0.39x	1.62x	Rs-1.13 Billion
2017	-1.42%	-2.04%	0.36x	1.95x	Rs-1.12 Billion
2018	65.10%	50.07%	0.63x	2.07x	Rs3.57 Billion
2019	6.89%	4.76%	0.74x	1.96x	Rs-220.09 Million
2020	10.17%	6.02%	0.79x	2.13x	Rs11.95 Million
2021	13.12%	7.06%	0.97x	1.91x	Rs226.77 Million
2022	5.92%	2.90%	0.97x	2.10x	Rs-282.55 Million
2023	-17.34%	-8.54%	0.93x	2.19x	Rs-1.91 Billion
2024	-5.46%	-2.63%	0.89x	2.35x	Rs-1.02 Billion
2025	3.11%	1.41%	0.97x	2.27x	Rs-485.67 Million

Industry Comparison

This section compares Sequent Scientific Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $23,713,303,062
Average return on equity (ROE) among peers: 8.81%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Sequent Scientific Limited (SEQUENT)	Rs8.87 Billion	18.94%	0.95x	$529.07 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$988.60 Million	6.59%	1.36x	$27.93 Million
Aarti Drugs Limited (AARTIDRUGS)	$6.52 Billion	21.67%	1.42x	$371.43 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$19.90 Billion	13.69%	0.46x	$725.68 Million
Abbott India Limited (ABBOTINDIA)	$36.99 Billion	32.48%	0.40x	$5.85 Billion
Ajanta Pharma Limited (AJANTPHARM)	$1.16 Billion	12.69%	1.32x	$3.81 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$6.25 Billion	-40.39%	3.91x	$906.19 Million
Alkem Laboratories Limited (ALKEM)	$88.47 Billion	18.60%	0.59x	$6.98 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.46 Billion	16.82%	0.29x	$178.52 Million
Alembic Pharmaceuticals Limited (APLLTD)	$51.90 Billion	11.24%	0.50x	$1.60 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$23.50 Billion	-5.26%	1.65x	$8.73 Billion

About Sequent Scientific Limited

NSE:SEQUENT India Drug Manufacturers - Specialty & Generic

Market Cap

$529.07 Million

Rs48.92 Billion INR

Market Cap Rank

#12249 Global

#578 in India

Share Price

Rs193.72

Change (1 day)

-3.70%

52-Week Range

Rs152.68 - Rs252.00

All Time High

Rs322.89